Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy

Abstract This retrospective study aimed to explore the relative efficacy and safety of different tacrolimus (TAC) concentrations in the treatment of patients with idiopathic membranous nephropathy (IMN). A total of 260 IMN patients with nephrotic syndrome (NS) were recruited. Among these, 125 patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qi Wang, Manna Li, Xuexin Cheng, Gaosi Xu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1e73ef2d075e4fcd9c8b55f89cf0977b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e73ef2d075e4fcd9c8b55f89cf0977b
record_format	dspace
spelling	oai:doaj.org-article:1e73ef2d075e4fcd9c8b55f89cf0977b2021-12-02T17:12:17ZClinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy10.1038/s41598-021-92678-y2045-2322https://doaj.org/article/1e73ef2d075e4fcd9c8b55f89cf0977b2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92678-yhttps://doaj.org/toc/2045-2322Abstract This retrospective study aimed to explore the relative efficacy and safety of different tacrolimus (TAC) concentrations in the treatment of patients with idiopathic membranous nephropathy (IMN). A total of 260 IMN patients with nephrotic syndrome (NS) were recruited. Among these, 125 patients had TAC concentrations no greater than 5 ng/ml (CTAC ≤ 5 ng/ml), and 135 patients had TAC concentrations greater than 5 ng/ml (CTAC > 5 ng/ml). The primary outcomes included complete remission (CR) rates and overall (OR) response rates. The secondary outcomes included 24-h urinary protein (24-h UP), serum albumin and serum creatinine, and adverse events (AEs). During the 12-month follow-up, the overall response rates were significantly different between the CTAC ≤ 5 ng/ml group and the CTAC > 5 ng/ml group (P < 0.0001). However, there was no significant difference in the CR at 12 months between the two groups (chi-square, 62% vs 63%, P = 0.852). Compared with the CTAC ≤ 5 ng/ml group, the CTAC > 5 ng/ml group had improved levels of 24 h UP (P = 0.017) and serum albumin (P = 0.010). Moreover, the incidences of acute reversible nephrotoxicity (P < 0.001), hepatotoxicity (P = 0.036), new-onset diabetes mellitus (P = 0.036), and glucose intolerance (P = 0.005) were lower in the CTAC ≤ 5 ng/ml group than in the CTAC > 5 ng/ml group. The CTAC > 5 ng/ml group was improved relative to the CTAC ≤ 5 ng/ml group in terms of a PR and CR at 6 months, but there was no difference in the CR between the two groups at 12 months.Qi WangManna LiXuexin ChengGaosi XuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Qi Wang Manna Li Xuexin Cheng Gaosi Xu Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
description	Abstract This retrospective study aimed to explore the relative efficacy and safety of different tacrolimus (TAC) concentrations in the treatment of patients with idiopathic membranous nephropathy (IMN). A total of 260 IMN patients with nephrotic syndrome (NS) were recruited. Among these, 125 patients had TAC concentrations no greater than 5 ng/ml (CTAC ≤ 5 ng/ml), and 135 patients had TAC concentrations greater than 5 ng/ml (CTAC > 5 ng/ml). The primary outcomes included complete remission (CR) rates and overall (OR) response rates. The secondary outcomes included 24-h urinary protein (24-h UP), serum albumin and serum creatinine, and adverse events (AEs). During the 12-month follow-up, the overall response rates were significantly different between the CTAC ≤ 5 ng/ml group and the CTAC > 5 ng/ml group (P < 0.0001). However, there was no significant difference in the CR at 12 months between the two groups (chi-square, 62% vs 63%, P = 0.852). Compared with the CTAC ≤ 5 ng/ml group, the CTAC > 5 ng/ml group had improved levels of 24 h UP (P = 0.017) and serum albumin (P = 0.010). Moreover, the incidences of acute reversible nephrotoxicity (P < 0.001), hepatotoxicity (P = 0.036), new-onset diabetes mellitus (P = 0.036), and glucose intolerance (P = 0.005) were lower in the CTAC ≤ 5 ng/ml group than in the CTAC > 5 ng/ml group. The CTAC > 5 ng/ml group was improved relative to the CTAC ≤ 5 ng/ml group in terms of a PR and CR at 6 months, but there was no difference in the CR between the two groups at 12 months.
format	article
author	Qi Wang Manna Li Xuexin Cheng Gaosi Xu
author_facet	Qi Wang Manna Li Xuexin Cheng Gaosi Xu
author_sort	Qi Wang
title	Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
title_short	Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
title_full	Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
title_fullStr	Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
title_full_unstemmed	Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
title_sort	clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1e73ef2d075e4fcd9c8b55f89cf0977b
work_keys_str_mv	AT qiwang clinicalefficacyandsafetyofdifferenttacrolimusconcentrationsforthetreatmentofpatientswithidiopathicmembranousnephropathy AT mannali clinicalefficacyandsafetyofdifferenttacrolimusconcentrationsforthetreatmentofpatientswithidiopathicmembranousnephropathy AT xuexincheng clinicalefficacyandsafetyofdifferenttacrolimusconcentrationsforthetreatmentofpatientswithidiopathicmembranousnephropathy AT gaosixu clinicalefficacyandsafetyofdifferenttacrolimusconcentrationsforthetreatmentofpatientswithidiopathicmembranousnephropathy
_version_	1718381422718222336

Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy

Ejemplares similares